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Abstract 
Background: Interstitial cystitis, or bladder pain syndrome (IC/BPS), is a chronic bladder disorder characterized by 
lower abdominal pain associated with the urinary bladder and accompanied by urinary frequency and urgency in the 
absence of identifiable causes. IC/PBS can be separated into the classic Hunner’s ulcerative type and the more preva-
lent non-ulcerative disease. Our aim was to unravel the biological processes and dysregulated cell signaling pathways 
leading to the bladder remodeling in non-ulcerative bladder pain syndrome (BPS) by studying the gene expression 
changes in the patients’ biopsies.
Methods: We performed paired microRNA (miRNA) and mRNA expression profiling in the bladder biopsies of BPS 
patients with non-Hunner interstitial cystitis phenotype, using comprehensive Next-generation sequencing (NGS) 
and studied the activated pathways and altered biological processes based on the global gene expression changes. 
Paired mRNA-miRNA transcriptome analysis delineated the regulatory role of the dysregulated miRNAs by identifying 
their targets in the disease-induced pathways.
Results: EIF2 Signaling and Regulation of eIF4 and p70S6K Signaling, activated in response to cellular stress, were 
among the most significantly regulated processes during BPS. Leukotriene Biosynthesis nociceptive pathway, impor-
tant in inflammatory diseases and neuropathic pain, was also significantly activated. The biological processes identi-
fied using Gene Ontology over-representation analysis were clustered into six main functional groups: cell cycle regu-
lation, chemotaxis of immune cells, muscle development, muscle contraction, remodeling of extracellular matrix and 
peripheral nervous system organization and development. Compared to the Hunner’s ulcerative type IC, activation 
of the immune pathways was modest in non-ulcerative BPS, limited to neutrophil chemotaxis and IFN-γ-mediated 
signaling. We identified 62 miRNAs, regulated and abundant in BPS and show that they target the mRNAs implicated 
in eIF2 signalling pathway.
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Background
Interstitial cystitis, or bladder pain syndrome (IC/BPS), 
is a chronic bladder disorder characterized by lower 
abdominal pain associated with the urinary bladder and 
accompanied by day-time and/or night-time urinary 
frequency and urinary urgency, in the absence of iden-
tifiable causes such as bacterial infection [1]. BPS affects 
people of different age groups with a higher prevalence in 
women (45 cases per 100,000) compared to men (8 cases 
per 100,000) [2]. An estimated 2.70% to 6.53% (or 3.3 to 
7.9 million) of US women 18 years old or older reported 
BPS/IC symptoms [3]. IC/PBS can be separated into two 
subtypes: classic Hunner’s ulcerative type, characterized 
by Hunner’s ulcers or haemorrhages in the bladder and 
the more prevalent non-ulcerative disease [4]. The aeti-
ology of BPS is unknown, and its treatment is largely 
empiric. The main cause of IC/PBS is thought to be a 
persistent bladder inflammation, possibly brought about 
by the deficiency of the glycosaminoglycan covering the 
urothelium surface that results in leaky urothelium and 
subsequent activation of afferent nerves and neurogenic 
inflammation. Growing evidence suggests that there is 
a morphological and functional distinction between IC/
BPS with Hunner lesions and IC/BPS without Hunner 
lesions: IC/BPS with Hunner lesions is an inflammatory 
disorder characterized by B cell abnormalities and epi-
thelial denudation, while IC/BPS without Hunner lesions 
shows minimal histological changes [5].
Studying gene expression changes in disease might 
shed light on the underlying biological processes and 
help developing specific therapies. Previously, inves-
tigating the expression levels of genes implicated in 
epithelial permeability, bladder contractility, and inflam-
mation, and the associated regulatory microRNAs in BPS 
patients’ bladder biopsies, we showed a significant down-
regulation of tight junction proteins zona occludens-1, 
junctional adherins molecule-1, and occludin, indicative 
of increased urothelial permeability, and concomitant 
up-regulation of bradykinin B(1) receptor, cannabinoid 
receptor CB1 and muscarinic receptors M3-M5, pointing 
to the inflammation-driven smooth muscle contractility 
activation []. BPS induced an up-regulation of acid-sens-
ing ion channel 2a and 3 mRNA in the bladder [6], while 
causing a decrease in the levels of anti-inflammatory 
annexin A1 in the urothelium [7].
Recent advances in Next-Generation Sequencing 
(NGS) allow comprehensive characterization of the gene 
expression profiles in different disease states, with subse-
quent pathway analysis revealing the involved pathoge-
netic mechanisms. To date, several transcriptome studies 
were carried out in human IC/BPS patients using gene 
expression microarrays in biopsies [8] and urine sedi-
ment [9]; QPCR panels of 96 inflammatory mediators 
[10], NGS in urine sediment [11] and bladder biopsies 
[12].
In order to investigate the pathogenetic changes and 
study the regulatory role of miRNAs in BPS, we per-
formed an integrated analysis of miRNA and mRNA 
paired expression profiling in the bladder biopsies of BPS 
human patients with non-Hunner IC phenotype, previ-
ously characterized by other methodology [7, 13], using 
comprehensive Next-generation sequencing (NGS)-
derived transcriptome data. We studied the activated 
pathways and altered biological processes based on the 
global gene expression changes and explored the pres-




Patient recruitment and cold cup bladder dome biopsy 
collection from 14 controls and 22 BPS patients was 
described in our earlier published study [13]. Permis-
sion to conduct this study was obtained from the Eth-
ics Committee of the Canton of Bern (KEK 146/05), and 
all subjects gave written informed consent. All subjects 
underwent a complete urological evaluation (including 
medical history, physical examination, urine culture, flex-
ible urethrocystoscopy). In addition, all subjects with the 
BPS underwent uroflowmetry, post void residual (PVR) 
and multichannel urodynamic investigations including 
filling cystometry and pressure-flow studies. All patients 
had confirmed BPS without Hunner’s lesions. Patient 
selection and evaluation was described previously [13]. 
Full information on patients is given in the Additional 
file 1. Patients were divided in 2 groups:
Conclusions: The bladders of non-ulcerative BPS patients recruited in this study had alterations consistent with 
a strong cell proliferative response and an up-regulation of smooth muscle contractility, while the contribution of 
inflammatory processes was modest. Pathway analysis of the integrated mRNA-miRNA NGS dataset pinpointed 
important regulatory miRNAs whose dysregulation might contribute to the pathogenesis. Observed molecular 
changes in the peripheral nervous system organization and development indicate the potential role of local bladder 
innervation in the pain perceived in this type of BPS.
Keywords: Bladder, Pain, Cystitis, Gene, miRNA, Signaling pathway, Next-generation sequencing
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1. Group 1: Control—asymptomatic patients undergo-
ing cystoscopy for other reasons (e.g. stent placement 
for stone disease, microhematuria evaluation, fistula 
closure) (n = 6 for NGS, n = 8 for QPCR validation). 
All QPCR controls and 2 out of 4 NGS controls 
were female, average age was 51.8 ± 21 (QPCR) and 
46.8 ± 6.7 (NGS).
2. Group 2: BPS—patients with pain (> 3 months) con-
sidered to be located in the bladder and/or frequency, 
urgency and nocturia (n = 6 for NGS, n = 16 for 
QPCR validation). All patients were female, average 
age 45.7 ± 15 (QPCR) and 38 ± 11 (NGS).
Biopsy samples from all subjects underwent a routine 
microscopic examination by a trained pathologist (H&E 
staining, staining for mast cell tryptase, staining for S100 
proteins and PGP 9.5 for nerve fibres). No patient had an 
increased postvoid residual. Urodynamic studies showed 
a median cystometric bladder volume of 200 ml (range 60 
– 1000), one patient had a high capacity bladder with a 
volume > 1000  ml and 2 patients had a normal capacity, 
all of the remaining ones had low capacity bladders. His-
topathological evaluation showed chronic inflammation 
(lymphoplasmocytic infiltration, interstitial edema and/
or hyperemia of the blood vessels with dilated lumina) in 
all but 4 patients, and 17 demonstrated increased mast 
cells (MC) in the smooth muscle (≥ 20 MC/mm2) (Addi-
tional file 1). Cold cup biopsies from the bladder dome, 
two biopsies per subject were collected and stored in 
RNAlater (Qiagen) at − 70 °C until RNA isolation. Total 
RNA was isolated from bladder dome biopsies using 
the miRVana miRNA isolation kit (Ambion) and the 
RNA quality controlled by BioAnalyzer. Six high-quality 
(RIN ≥ 9) RNA samples were randomly selected for NGS.
miRNA and mRNA sequencing and pathway analysis
Illumina miRNA and mRNA Sequencing
Both miRNA and mRNA sequencing was performed on 
the Illumina HiSeq 2000 using RNA isolated from the 
same patient’s biopsy. NGS protocol is described in our 
previous study [14]. Briefly, sequencing was performed 
on the Illumina HiSeq 2000 single end 100 bp using the 
TruSeq SBS Kit v3-HS (Illumina, Inc, California, USA). 
For mRNA-seq, read mapping to human reference 
genome hg19 was done using Tophat 2.0.9. Counting the 
number of reads/gene was done using HTSeq v.0.5.4p3. 
The Bioconductor packages DESeq2 and edgeR (Bio-
conductor version: Release (3.2)) were used to identify 
differentially expressed genes. We set the threshold for 
FDR-adjusted p value to 0.15 in order to maximize the 
number of genes used to build the pathways. The miRNA 
Target Filter tool in IPA (IPA®, QIAGEN Redwood City, 
http:// www. qiagen. com/ ingen uity was used to associate 
miRNAs from our miRNA sequencing datasets with 
experimentally observed and predicted mRNA targets. 
The predicted relationships are from TargetScan (v7.0; 
targetscan.org) and the experimentally observed relation-
ships are from TarBase.
Hierarchical clustering and heatmaps
Hierarchical clustering and the associated heatmaps for 
miRNA and mRNA sequencing data were generated with 
the function heatmap2 in the R package gplots or GENE-
E R package. Pairwise correlation matrix between items 
was computed (based on Pearson correlation method) 
and then converted as a distance matrix and finally clus-
tering was computed on the resulting distance matrix. 
Average linkage method used average to calculate the 
distance matrix. For the heatmap visualization, the log2-
expression values were used.
Principal component analysis (PCA)
For a principal component analysis on log2 fold change of 
mRNA and microRNA expression of patients compared 
to controls, ‘prcomp’ function implemented in R (R Core 
Team, 2016), rgl and scatterplot3d R package was used 
for the principal component analysis of three-dimensions 
plots. To achieve a better numerical accuracy, the calcu-
lation was done by a singular value decomposition of the 
(centered and scaled) data matrix.
Gene and miRNA clouds (tag clouds, word clouds)
To condense and visualize gene enrichment data from 
a pathway analysis dataset a cloud was created using 
Wordle.net and Word cloud R package. The font size of 
a gene or miRNA (tag) is determined by its incidence in 
the pathway analysis dataset.
Functional enrichment analysis
Gene Ontology (GO) over-representation analysis (ORA) 
[15] methods were used to gain biological insight on the 
DEGs. We used clusterProfiler (version 3.18.1) package 
[16] in R  to perform GO-ORA and GO-GSEA on bio-
logical process (BP) terms associated with DEGs. Results 
obtained at a threshold of p value below 0.1 were consid-
ered statistically significant.
QPCR validation of NGS studies
Total RNA was isolated from bladder dome biopsies 
using the miRVana miRNA isolation kit (Ambion). The 
reverse transcription reactions were carried out using the 
High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems) with random hexamer primers. TaqMan 
assays were from Applied Biosystems. QPCR was carried 
out in triplicates using 7900HT Fast Real-time PCR Sys-
tem (Applied Biosystems). The Ct values obtained after 
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the real time-QPCR were normalized to 18S expression 
and fold differences compared to the average of controls 
calculated.
NanoString nCounter analysis
miRNA presence and content were analysed with 
the nCounter Human miRNA Expression Assay kit 
(NanoString, Seattle, WA) according to manufacturer’s 
instructions with some modifications, as described in 
our earlier publication [17]. Briefly, 3  µl of each total 
RNA sample was used as input into the nCounter Human 
miRNA sample preparation. Hybridization was con-
ducted for 12  h at 65  °C. Subsequently, the strip tubes 
were placed into the nCounter Prep Station for auto-
mated sample purification and subsequent reporter 
capture. Each sample was scanned for 600 FOV on the 
nCounter Digital Analyzer. The R Packages were used 
for NanoString Data Analysis: “NanoStringNorm” and 
“NanoStringDiff" (Available in CRAN). Background cor-
rection was performed based on the detected values of 
negative control probes, a within-sample normalization 
was calculated based on the observed values of positive 
control probes and normalization across samples using 
reference (housekeeping) genes. Additionally, we used a 
new algorithm called Removing Unwanted Variation-III 
(RUV-III) [18] which employs technical replicates and 
suitable control genes to normalise the data. “EdgeR" was 
used for expression profiling.
Statistics
Hierarchical clustering and heatmaps
Hierarchical clustering and the associated heatmaps for 
miRNA and mRNA sequencing data were generated with 
the function heatmap2 in the R package gplots or GENE-
E R package. Pairwise correlation matrix between items 
was computed based on Pearson correlation method. 
Average linkage method used average to calculate the 
distance matrix. For the heatmap visualization the log2-
expression values were used. We used dendextend R 
package to create and compare visually appealing tree 
diagrams. Principal Component analysis (PCA). ‘Prcomp’ 
function implemented in R (R Core Team, 2016), rgl and 
scatterplot3d R package were used for the principal com-
ponent analysis of three-dimensions plots. The calcula-
tion was done by a singular value decomposition of the 
(centered and scaled) data matrix. For QPCR validation 
the log2 fold change differences to the average of control 
samples were calculated. A one-way analysis of variance 
(ANOVA) was employed and the Tukey correction used 
to correct p values. The p value < 0.05 was considered 
statistically significant (GraphPad Prism (version 7.01)). 
Contingency analysis. Graphical matrix was drawn using 
the function balloonplot() in gplots package in R.
Results
Differentially expressed genes in BPS compared to control
Differentially expressed genes (DEGs, mRNAs and miR-
NAs) were determined in BPS group using DESeq2 (with 
p value < 0.05, absolute log2 fold change > 0.5 and mean 
of read counts > 50 reads). Figure 1A shows the heatmap 
and hierarchical clustering based on normalized read 
counts of all significantly regulated mRNAs. Patients with 
BPS (“pain1-5”) cluster away from controls, although 
patient “pain6” more closely resembles controls in its 
DEGs profile. Selection of the 84 top regulated mRNAs 
(p value < 0.05, absolute log2 fold change > 1 and mean of 
read counts > 50 read) helped to cluster the two groups 
better (see the dendrogram in Additional file 8: Fig. S1A). 
PCA based on mRNAseq data shows good separation of 
BPS patients from controls (Fig.  1B). The scree plot in 
Additional file 8: Fig. S1B shows that component 1 and 2 
can cover more than 75% of variation between samples. 
(See figure on next page.)
Fig. 1 Differentially expressed mRNAs and miRNAs in BPS patients. A Heatmap and hieratical clustering based on normalized read counts of all 
mRNA (829) with p value < 0.05, absolute log2 fold change > 0.5 and mean of read counts > 50 reads. Genes are represented in y-axis and patients 
with BPS and controls are shown in x-axis. Normalized read counts were used for this heatmap. Minimum and maximum renormalized read counts 
for each mRNA were used to construct a relative color scheme by convert values to colors. One minus Pearson correlation metric was used for 
clustering accompanied with average linkage method. B Principal component analysis of the RNA sequencing data in a 2D graph of PC1 and PC2 
based on normalized read counts of all mRNA (829) with p value < 0.05, absolute log2 fold change > 0.5 and mean of read counts > 50 reads. The 
bi-plot shows samples as labelled dots. Values of cos2 (square cosine, squared coordinates) for each sample indicate the quality of representation 
of the variables on the factor map. Samples are colour coded according to cos2 scale shown in the bar. C Volcano plot of all mRNAs. Up-regulated 
mRNAs are visualized in red color, and down-regulated in green. mRNAs with p value < 0.05, absolute log2 fold change > 0.5 were selected for 
further analysis. D Heatmap and hieratical clustering of all miRNA (62) with p value < 0.05, absolute log2 fold change > 0.5 and mean of read 
counts > 50 read. miRNAs are represented in y-axis and patients with BPS and controls are shown in x-axis. Normalized read counts were used for 
this heatmap. Minimum and maximum renormalized read counts for each miRNA were used to construct a relative color scheme by convert values 
to colors. One minus Pearson correlation metric was used for clustering accompanied with average linkage method. E Principal component analysis 
of the miRNA data in a 2D graph of PC1 and PC2. PC2 based on normalized read counts of all miRNA (62) with p value < 0.05, absolute log2 fold 
change > 0.5 and mean of read counts > 50 reads. The bi-plot shows samples as labelled dots. Samples are colour-coded according to the quality of 
representation of the variables on factor map (cos2, square cosine, squared coordinates) as shown on the side-bar. F Volcano plot of all miRNAs. All 
up-regulated miRNAs are visualized in red color, and all down-regulated in green. miRNAs with p value < 0.05, absolute log2 fold change > 0.5 were 
selected for further analysis
Page 5 of 13Gheinani et al. BMC Urology          (2021) 21:172  
Fig. 1 (See legend on previous page.)
Page 6 of 13Gheinani et al. BMC Urology          (2021) 21:172 
To characterize the relationship between 15 top regu-
lated genes and each single patient in mRNA data set, a 
contingency analysis was performed. TPPP3, CRIP1, and 
MFAP5 showed a higher the probability of being indica-
tive for BPS group (Additional file 8: Fig. S1C). DESeq2 
analysis resulted in 829 differentially expressed mRNAs 
(Additional file  2). Overall, we identified 574 up-regu-
lated and 255 down-regulated genes. Volcano plot of sig-
nificantly regulated mRNAs based on p value (Fig. 1C) or 
adjusted p value (Additional file  8: Fig. S1) showed that 
TPPP3 and CRIP1 are the most up-regulated genes while, 
MET and FAM83A are most down-regulated genes.
The hierarchical clustering of samples based of differ-
entially expressed miRNAs was very similar to the one 
based on mRNAs (Fig. 1D), likewise sample “pain6” was 
more similar to the controls than the rest of the samples. 
In totals, 62 miRNAs were changed during BPS, and PCA 
based on their normalized read counts clearly differenti-
ated BPS from controls (Fig. 1E). The scree plot shown in 
Additional file  8: Fig. S2B shows that component 1 and 
2 can cover more than 72% of variation between sam-
ples. The significant differentially expressed miRNAs are 
shown as a volcano plot (Fig. 1F). The background data 
to the miRNA analysis are shown in Additional file 8: Fig. 
S2.
Functional enrichment analysis and identification 
of dysregulated biological processes in BPS
Using IPA, 31 significant pathways were built, though 
most did not have a defined z-score indicative of whether 
the activity of canonical pathways, including functional 
end-points, is increased or decreased based on DEGs 
in the datasets. Top 5 canonical IPA pathways based on 
mRNA datasets are shown in Table 1 (full list of pathways 
in Additional file 3). The two pathways involved in trans-
lational regulation, EIF2 Signalling and Regulation of 
eIF4 and p70S6K Signalling, are among the most signifi-
cantly regulated processes during BPS. Fibrotic pathway 
important for bladder remodelling is also significant but 
without a z-score indicative of up- or down-regulation. 
Leukotriene Biosynthesis nociceptive pathway is signifi-
cantly activated (positive z-score).
In order to gain insight into the biological processes 
underlying BPS, we resorted to Gene Ontology (GO) 
Over Representation Analysis (ORA). The GO terms 
and associated genes, obtained from the ORA result 
are listed Additional file  4. To gain a better insight into 
the GO terms network, we created a semantic similar-
ity matrix for a given list of GO terms depending on the 
information content of their closest common ancestor 
term. After removing the redundant GO terms based on 
semantic similarity score threshold of 0.7, remaining GO 
terms were grouped by clustering the semantic similar-
ity matrix using binary cut method. A treemap view of 
GO-term clusters, where each tile and colour represent 
a term and cluster respectively, is shown in Fig.  2A. In 
the treemap plot, tile size and group representatives of 
each cluster corresponds to the GO terms’ size. Processes 
involved in cell division are highly represented in the BPS 
dataset, based on the abundance of mitosis-connected 
GO terms (Fig.  2A), followed by ECM reorganisation, 
neutrophil chemotaxis and muscle contractility. Nota-
bly, peripheral nervous system development is a promi-
nent feature of this dataset. Figure  2B represents these 
Table 1 Top 5 canonical IPA pathways regulated in BPS based on p value
Ingenuity canonical pathways −log(p value) Ratio z-score Molecules
EIF2 signalling 9.15 0.125 3.771 DDIT3 EIF2AK3 EIF3G FAU MAP2K2 RPL10A RPL13 RPL18 RPL18A 
RPL24 RPL27 RPL28 RPL29 RPL35 RPL36 RPL37 RPL38 RPLP1 RPLP2 
RPS15 RPS15A RPS16 RPS19 RPS21 RPS4X RPS7 RPS9 RRAS
Hepatic fibrosis/hepatic stellate cell activation 4.54 0.0968 NA CCL2 CCL21 CCN2 COL18A1 COL19A1 COL22A1 COL4A2 COL6A1 
COL6A2 COL9A3 CXCL9 IGFBP4 MET MYL6 MYL9 STAT1 TIMP1 VEGFB
Leukotriene biosynthesis 3.24 0.308 2 DPEP2 GGT1 GGT5 LTC4S
Regulation of eIF4 and p70S6K Signalling 2.81 0.0828 NA EIF3G FAU ITGA2 MAP2K2 RPS15 RPS15A RPS16 RPS19 RPS21 RPS4X 
RPS7 RPS9 RRAS
Cholesterol biosynthesis 2.69 0.172 − 2.236 HMGCR HMGCS1 MSMO1 SC5D SQLE
Fig. 2 Gene ontology over-representation analysis of regulated mRNAs in BPS patients. A A treemap view of GO-term clusters, where each tile and 
colour represent a term and cluster, respectively. The list of GO terms was converted into a semantic similarity matrix using binary cut method. Tile 
size and group representatives of each cluster are corresponding to the GO terms’ size. B GO terms as clusters. Regulation of cell cycle, neutrophil 
chemotaxis and muscle and nervous system development are the top 3 clusters for BPS
(See figure on next page.)
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Fig. 2 (See legend on previous page.)
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GO terms as clusters, clustered by binary cut method. 
There, regulation of cell cycle, neutrophil chemotaxis and 
muscle and nervous system development are the top 3 
clusters for BPS. We identified functional modules using 
Enrichment Map plot (Fig.  3). The network of enriched 
terms with edges connecting overlapping gene sets clus-
tered mutually overlapping gene sets, visualizing the six 
main functional modules for BPS: cell cycle regulation, 
chemotaxis of immune cells, muscle development, mus-
cle contraction, remodelling of extracellular matrix and 
peripheral nervous system organization and development 
(Fig.  3). To confirm the NGS results, we investigated 
the expression levels of 4 selected mRNAs, including 
the top regulated FAM83A and TPPP3 (Fig.  1C) in the 
bladder biopsies of a larger independent patient cohort 
(n = 8 controls and n = 16 BPS). mRNAs for TPPP3, 
ANGPTL17 and MFAP5 were significantly up-regulated 
(p < 0.05), whereas FAM83A was down-regulated in BPS, 
in accordance with the NGS data (Fig. 4).
Identification of functionally important miRNAs altered 
in BPS dataset
We identified 62 microRNAs, regulated and abundant 
in BPS (Additional file 5) and determined which of their 
target mRNAs were present and correctly regulated in 
the mRNA dataset (Additional file 6). The word cloud in 
Fig. 5A illustrates the miRNAs, with the font size reflect-
ing the number of correctly regulated target mRNAs. Up-
regulated miR-424-5p and down-regulated miR-34a-5p 
have 40 and 45 regulated target genes in mRNA dataset, 
respectively, and potentially play the highest regulatory 
role in BPS. Word cloud of the miRNA targets includes 
TNFSF15, TSPAN4 and WDFY4 mRNAs which are tar-
geted by multiple miRNAs (Fig.  5B). MiRNA-regulated 
genes fall into multiple categories, the majority being 
enzymes, transcriptional regulators, transporters and 
kinases.
Multiple cytokines differentially expressed in the 
BPS dataset are paired with their regulatory miRNAs 
Fig. 3 Enrichment Map plot of GO ORA (mRNA dataset). The network of enriched terms with edges connecting overlapping gene sets clusters 
mutually overlapping gene sets, visualizing the six main functional modules for BPS
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(Fig. 5C): CCL21 is increased, while miR-205-5p which 
is predicted to target it, is down-regulated; the same 
correct behaviour was observed for the down-regulated 
CCL2, CXCL10, CXCL9, whose regulatory miRNAs 
were all increased (Fig. 5C). Similarly, the up-regulated 
components of the activated EIF2 signalling pathway 
are regulated by miRNAs which are decreased in the 
biopsies of patients with BPS (Fig. 5D). Top ten signifi-
cant IPA pathways built using appropriately regulated 
targets of miRNAs are shown in Fig.  5E. Like in the 
mRNA dataset shown in Fig.  5F for comparison, eIF2 
signalling is the main activated pathway, targeted by 
miRNAs regulated in BPS.
To validate the miRNA expression results, we carried 
out a profiling study using NanoString nCounter Human 
miRNA Expression Assay kit (Additional file  7) using 
n = 7 controls and n = 16 BPS samples. Comparative reg-
ulation of 16 miRNAs, robustly detected by NanoString 
in all samples, is shown in Additional file 8: Fig. S3. We 
confirmed the down-regulation of miR-205-5p, and up-
regulation of muscle-specific miR-145-5p, miR-143-3p 
and miR-133a-3p in BPS patients.
Discussion
IC/BPS is a chronic disease of unknown etiology, it is a 
multifactorial, heterogeneous disorder with several clini-
cal phenotypes. A variety of pathophysiological origins 
have been proposed for BPS, ranging from autoimmun-
ity, inflammation caused by recurrent bladder injury, 
neurogenic inflammation with the contributing increase 
of urothelial permeability and disruption of the GAG 
layer, and altered central nociception [4, 5]. Emerging 
gene expression studies, using human tissue (bladder 
biopsies or urine sediment) or tissue from animal models 
of IC have shed some light on bladder alterations during 
BPS, however, no consensus exists regarding the molecu-
lar drivers of this dysfunction. Recent findings indicate 
that IC/BPS with Hunner’s lesions is a distinct histologi-
cal and molecular phenotype of the disease, character-
ized by pancystitis, frequent clonal B-cell expansion and 
epithelial denudation [19]. Therefore, current guidelines 
[20] suggest that Hunner-type interstitial cystitis and 
bladder pain syndrome should be considered separate 
entities, because bladder pain syndrome shows minimal 
pathological changes in the bladder [20]. While the gene 
expression profile of Hunner-type IC seems quite distinct 
from the controls, both in the biopsies and urine sedi-
ment [11, 12], the patients with non-ulcerative BPS/IC 
are less clearly definable, and often show no or slight dif-
ferences in gene expression compared to control either in 
the biopsies [12], or urine sediment [9].
In this study we analyzed the NGS mRNA and miRNA 
gene expression profiles in the bladder dome biopsies 
of female patients with BPS. Unlike many earlier gene 
expression studies, performed using low throughput 
Fig. 4 QPCR validation of selected DEGs based on NGS mRNA 
dataset. QPCR results for 4 mRNAs, regulated and significant (p < 0.05) 
in NGS mRNA dataset. Gene expression was determined in RNA 
samples isolated from controls (n = 8) and BPS patients’ biopsies 
(n = 16) using TaqMan gene expression The Ct values obtained after 
the real time-QPCR were normalized to 18S rRNA expression and fold 
differences compared to the average of controls calculated. Boxplot 
of log2 fold changes relative to the average normalized Ct values 
in the control group is shown. Statistically significant differences 
(*p < 0.05, ***p < 0.001, ANOVA)
(See figure on next page.)
Fig. 5 Pathway analysis using mRNAs, targeted by miRNAs regulated in BPS. A Role of miRNAs depending on the number of their appropriately 
regulated targets. Word cloud of up-regulated (in red) and down-regulated (in green) miRNAs, font size corresponding to the number of correctly 
regulated mRNAs, targeted by each specific miRNA. B Word cloud of mRNAs, targeted by dysregulated miRNAs; font size corresponds to the 
number of miRNAs affecting the expression of a particular mRNA. The coloured circle shows the functional groups of the affected mRNAs: most are 
enzymes and transcription regulators, kinases and cytokines. C Cytokines up-regulated (red) and down-regulated (green) and the targeting miRNAs. 
Note that some cytokines are affected by several miRNAs, and some miRNAs regulate multiple cytokine mRNAs. D EIF2 signalling pathway might be 
activated due to the down-regulation of miRNAs, targeting its elements. Down-regulated miRNAs are shown in green, up-regulated target genes in 
red. E Pathway analysis based on genes, predicted to be targeted by dysregulated miRNAs and differentially expressed in BPS. Top 10 IPA Pathways 
are shown (based on p value). F Pathway analysis based on all regulated mRNAs in BPS, top 10 pathways are shown
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methodology (microarrays, PCR arrays with selected 
genes), we carried out a comprehensive paired mRNA 
and miRNA transcriptome analysis from the same 
patient, allowing us to discern the involvement of particu-
lar miRNA targets in the signalling events. The patient 
group selected in our trial was not specifically recruited 
Fig. 5 (See legend on previous page.)
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based on the presence of Hunner’s ulcers, our patients 
did not have the ulcerative phenotype, and  therefore we 
refer to them as BPS. Most patients in our study had a 
low bladder capacity with median cystometric bladder 
volume of 200 ml, and a measurable infiltration of neu-
trophils and mast cells in the bladder submucosa. The 
NGS mRNA and miRNA gene expression profiles in our 
BPS patients (n = 6) were distinct from the controls. This 
is in agreement with previous findings, pointing to the 
correlation of gene expression with bladder capacity [8], 
where the patients with normal bladder capacity were 
similar to controls, and patients whose bladder volume 
ranged from 300 to 175 ml were significantly different.
We could use the DEGs mRNA dataset to build IPA 
pathways, though only a limited number of significant 
pathways could be assigned a z-score. Nevertheless, two 
out of top 5 pathways were involved in translational regu-
lation. EIF2 Signalling and Regulation of eIF4 and p70S6K 
Signalling are among the most significantly regulated 
processes during BPS. They are activated in response to 
cellular stress and regulate proinflammatory cytokine 
expression [21]. Importantly, both pathways were pre-
viously described in the urine sediment cells from BPS 
patients [11], highlighting the importance of cellu-
lar stress in the pathogenesis of BPS. Fibrotic pathway 
appears to be involved, pointing to organ remodelling. 
Leukotriene Biosynthesis nociceptive pathway, impor-
tant in a variety of allergic/inflammatory diseases and in 
neuropathic pain [22], is also significantly activated (posi-
tive z-score). Leukotrienes are produced and released by 
neutrophils and mast cells, which are increased in our 
population of BPS patients. Mast cell marker tryptase 
(TPSAB1 gene) was strongly and significantly upregu-
lated in the BPS NGS dataset (Log2 fold change (log2 FC) 
of 1.16, p value 0.004).
Previously, attempts have been made to distinguish 
BPS/IC from OAB using immunohistochemistry with 
antibodies to the nerve cell marker PGP9.5 (neuron-
specific protein gene product 9.5), p75NTR (p75 neuro-
trophin receptor), the B-lymphocyte marker CD20 and 
mast cell tryptase [23]. Clinically, patients with OAB are 
similar to patients with BPS/IC regarding frequency and 
urgency as well as low bladder capacity but usually do not 
suffer from pain. In addition to the increase of tryptase 
mRNA, we observed an up-regulation of PGP9.5 gene 
UCHL1 (log2 FC 0.56), and p75 neurotrophin receptor 
gene NTRK1 (log2 FC 1.24) in our dataset, indicative 
of sensory hyperinnervation in BPS. Similarly, several 
inflammatory mediators, identified earlier by QPCR in 
trigone biopsies of BPS patients using TaqMan microflu-
idic cards [10], showed similar regulation of expression: 
CCL21 (log2 FC 1.15, p value 0.01) and CXCL1 (log2 
FC 0.76) mRNAs were both significantly up-regulated 
in our NGS dataset. We observed that many regulatory 
miRNAs, altered during BPS, were involved in the regu-
lation of inflammatory mediators, and that the levels of 
CCL21 and its regulatory miR-205-5p were inversely 
correlated. Chemokine CCL21 activates microglia in the 
central nervous system and is expressed in neurons after 
an insult or mechanical injury, implicated in neuropathic 
pain [24], rheumatoid arthritis [25] and pulmonary 
fibrosis [26]. CCR7, the receptor for CCL21, was also 
up-regulated in the NGS dataset (log2 FC 0.66, n.s.), so 
it is possible that at least in some BPS patients, the rel-
evant signalling cascade is activated, contributing to the 
activation of the ERK and JNK pathways. Recent studies 
have linked bladder inflammation with mood disorders 
[27]. Although we did not specifically examine this, it is 
tempting to speculate that the up-regulation of CCL21 
reported here might have a bearing on the higher than 
average incidence of depression, common in BPS [28, 29].
We performed GO ORA using DEGs from the BPS 
mRNAseq dataset to reveal the biological processes con-
tributing to bladder remodelling. The pathways were 
clustered into six main functional groups: cell cycle regu-
lation, chemotaxis of immune cells, muscle development, 
muscle contraction, remodelling of extracellular matrix 
and peripheral nervous system organization and devel-
opment. Generally, immune pathways activation, which 
was a prominent feature of BOO-induced bladder over-
activity, and BPH-induced bladder remodelling [14] was 
modest in our dataset, limiting itself to neutrophil chem-
otaxis and IFN-γ-mediated signalling. Our data support 
the notion that, unlike Hunner-type IC, inflammation 
is less pronounced in non-ulcerative BPS, although it 
might play an important role in disease pathogenesis. 
Activation of mitosis, catabolic connective tissue remod-
elling and muscle tissue development, observed on the 
molecular level in our dataset, are in line with the blad-
der morphology of the majority of our subjects, who had 
thick-walled, low capacity bladders.
Our study has its limitations: only female patients have 
been recruited; controls for QPCR were also female, but 
NGS controls included 4 male subjects. To overcome 
the last limitation, the expression of the Y chromosome-
linked genes was not considered in the DEG analysis. The 
study has a relatively small number of patients, which 
might have a bearing on our results, given the heteroge-
neity of BPS.
In conclusion, we studied the gene expression pro-
files of mRNA and miRNA in bladder biopsies of 
BPS patients, and identified the key biological func-
tions, contributing to organ remodelling. Non-ulcer-
ative BPS patients, recruited in this study, had strong 
smooth muscle contractile and cell proliferative phe-
notype, indicative of smooth muscle hyperplasia. The 
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contribution of inflammatory processes was modest, 
but we observed molecular changes indicative of neu-
roinflammation and peripheral nervous system re-
organization and development. Pathway analysis of the 
integrated mRNA-miRNA NGS dataset shed some light 
on the molecular changes in the bladders of patients 
with BPS, and pinpointed important regulatory miR-
NAs whose dysregulation might contribute to the 
pathogenesis.
Abbreviations
IC/BPS: Interstitial cystitis/bladder pain syndrome; NGS: Next-generation 
sequencing; DEGs: Differentially expressed genes; mRNA: Messenger RNA; 
miRNA: MicroRNA; GO ORA: Gene ontology over-representation analysis; 
QPCR: Quantitative real-time polymerase chain reaction; eIF2(4): Eukaryotic 
Initiation Factor 2 (4); FC: Fold change; n.s.: Not significant.
Supplementary Information
The online version contains supplementary material available at https:// doi. 
org/ 10. 1186/ s12894- 021- 00934-0.
Additional file 1. Demographical and clinical information about the 
subjects participating in the study.
Additional file 2. List of differentially expressed genes with p-value<0.05, 
absolute log2 fold change>0.5 and mean of read counts>50 reads.
Additional file 3. List of significant Ingenuity Canonical Pathways
Additional file 4. Gene Ontology (GO) terms and associated genes, 
obtained from the Over Representation Analysis (ORA) with adjusted p 
value < 0.1
Additional file 5. List of abundant microRNAs, significantly regulated in 
the BPS patients compared to controls
Additional file 6. List of the mRNA targets of 62 miRNAs, abundant and 
regulated in BPS
Additional file 7. All data on miRNAs, detected in the profiling using 
NanoString nCounter Human miRNA Expression Assay kit
Additional file 8: Supplementary Figures. Fig. S1. Characterization of 
regulated mRNAs. (A) Sample clustering based on the expression of the 
84 top regulated mRNAs (p value<0.05, absolute log2 fold change>1 
and mean of read counts>50 read). (B) Scree plot for visualization of 
the percentage of variances explained for each principle component 
(eigenvalues) in RNA sequencing data (C) Contingency table of the 18 top 
regulated mRNAs displaying the (multivariate) frequency distribution of 
the variables. The diameter of the orange circle for each gene per patient 
provides an estimate of the probability for that particular gene to repre-
sent that particular patient. (D) Volcano plot of all mRNAs using adjusted P 
value. Fig. S2. Characterization of regulated miRNAs. (A) Sample clustering 
based on the expression of the 18 top regulated miRNAs (p-value<0.05, 
absolute log2 fold change>1 and mean of read counts>50 read) (B) Scree 
plot for visualization of the variances in miRNA sequencing data (C) Con-
tingency table of the 8 top regulated miRNAs displaying the (multivariate) 
frequency distribution of the variables. The diameter of the orange circle 
for each miRNA per patient provides an estimate of the probability for 
that particular miRNA to represent that particular patient. (D) Volcano 
plot of all miRNAs using adjusted P value. Fig. S3. Validation of regulated 
miRNAs by NanoString. Radar graph visualizing the average log2 fold 
change of 16 miRNAs significantly regulated in NanoString or sequencing 
dataset (p-value<0.05, absolute log2 fold change>1 and mean of read 
counts>300 read). The red line represents the NGS miRNA sequencing 
data and purple line represents the NanoString data. Red area is showing 
the upregulation and green area is representing downregulation.
Acknowledgements
Authors thank Dr Veronica Sanchez Freire for expert technical support at the 
beginning of this work.
Authors’ contributions
KM, FCB and AHG planned the study; AK and FCB recruited the patients, MB 
and KM performed sample preparation and QPCR validation; AHG and AA 
analysed the data; IK, RB and HR performed NGS and provided bioinformatic 
support, AHG, RMA and KM wrote the manuscript. All authors read and 
approved the final manuscript.
Funding
We gratefully acknowledge the financial support of the Swiss National Science 
Foundation (SNF Grant 310030_175773 to FCB and KM) and Novartis Founda-
tion for medical-biological research (Grant 19A035 to KM). AHG and RMA are 
supported by R01 DK104641 and R01 DK 077195.
Availability of data and materials
The mRNA- and miRNA-seq datasets were deposited in the European Nucleo-
tide Archive (ENA) under ENA accession numbers: PRJEB46961 for mRNA and 
PRJEB10955 for miRNA. The lists of genes used for downstream analysis and 
regulated genes involved in signalling pathways are available as Additional 
files.
Declarations
Ethics approval and consent to participate
Permission to conduct this study was obtained from the Ethics Committee 





No direct or indirect commercial, personal, academic, political, religious or 
ethical incentive is associated with publishing this article.
Author details
1 Functional Urology Research Group, Department for BioMedical Research 
DBMR, University of Bern, Bern, Switzerland. 2 Urological Diseases Research 
Center, Boston Children’s Hospital, Boston, MA, USA. 3 Department of Surgery, 
Harvard Medical School, Boston, MA, USA. 4 Broad Institute of MIT and Harvard, 
Cambridge, MA, USA. 5 Department of Gynaecology, Inselspital University 
Hospital, 3010 Bern, Switzerland. 6 Interfaculty Bioinformatics Unit, University 
of Bern, Bern, Switzerland. 7 Functional Genomics Center Zurich, ETH Zurich/
University of Zurich, Zurich, Switzerland. 8 Department of Urology, Inselspital 
University Hospital, 3010 Bern, Switzerland. 
Received: 31 August 2021   Accepted: 29 November 2021
References
 1. van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni 
M, Daha LK, et al. Diagnostic criteria, classification, and nomenclature for 
painful bladder syndrome/interstitial cystitis: an ESSIC proposal. EurUrol. 
2008;53(1):60–7.
 2. Clemens JQ, Meenan RT, Rosetti MC, Gao SY, Calhoun EA. Prevalence 
and incidence of interstitial cystitis in a managed care population. J Urol. 
2005;173(1):98–102; discussion https:// doi. org/ 10. 1097/ 01. ju. 00001 46114. 
53828. 82.
 3. Berry SH, Elliott MN, Suttorp M, Bogart LM, Stoto MA, Eggers P, et al. 
Prevalence of symptoms of bladder pain syndrome/interstitial cystitis 
among adult females in the United States. J Urol. 2011;186(2):540–4. 
https:// doi. org/ 10. 1016/j. juro. 2011. 03. 132.
 4. Karamali M, Shafabakhsh R, Ghanbari Z, Eftekhar T, Asemi Z. Molecular 
pathogenesis of interstitial cystitis/bladder pain syndrome based on 
Page 13 of 13Gheinani et al. BMC Urology          (2021) 21:172  
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
gene expression. J Cell Physiol. 2019;234(8):12301–8. https:// doi. org/ 10. 
1002/ jcp. 28009.
 5. Akiyama Y, Luo Y, Hanno PM, Maeda D, Homma Y. Interstitial cystitis/blad-
der pain syndrome: the evolving landscape, animal models and future 
perspectives. Int J Urol. 2020;27(6):491–503. https:// doi. org/ 10. 1111/ iju. 
14229.
 6. Sanchez-Freire V, Blanchard MG, Burkhard FC, Kessler TM, Kellenberger 
S, Monastyrskaya K. Acid-sensing channels in human bladder: expres-
sion, function and alterations during bladder pain syndrome. J Urol. 
2011;186(4):1509–16. https:// doi. org/ 10. 1016/j. juro. 2011. 05. 047.
 7. Monastyrskaya K, Babiychuk EB, Draeger A, Burkhard FC. Down-regulation 
of annexin A1 in the urothelium decreases cell survival after bacterial 
toxin exposure. J Urol. 2013. https:// doi. org/ 10. 1016/j. juro. 2013. 01. 088.
 8. Colaco M, Koslov DS, Keys T, Evans RJ, Badlani GH, Andersson KE, et al. 
Correlation of gene expression with bladder capacity in interstitial cysti-
tis/bladder pain syndrome. J Urol. 2014;192(4):1123–9. https:// doi. org/ 10. 
1016/j. juro. 2014. 05. 047.
 9. Blalock EM, Korrect GS, Stromberg AJ, Erickson DR. Gene expression 
analysis of urine sediment: evaluation for potential noninvasive markers 
of interstitial cystitis/bladder pain syndrome. J Urol. 2012;187(2):725–32. 
https:// doi. org/ 10. 1016/j. juro. 2011. 09. 142.
 10. Offiah I, Didangelos A, Dawes J, Cartwright R, Khullar V, Bradbury EJ, et al. 
The expression of inflammatory mediators in bladder pain syndrome. Eur 
Urol. 2016;70(2):283–90. https:// doi. org/ 10. 1016/j. eururo. 2016. 02. 058.
 11. Izquierdo L, Mateu L, Lozano JJ, Montalbo R, Ingelmo-Torres M, Gómez A, 
et al. Urine gene expression profiles in bladder pain syndrome patients 
treated with triamcinolone. Eur Urol Focus. 2020;6(2):390–6. https:// doi. 
org/ 10. 1016/j. euf. 2018. 10. 001.
 12. Akiyama Y, Maeda D, Katoh H, Morikawa T, Niimi A, Nomiya A, et al. 
Molecular taxonomy of interstitial cystitis/bladder pain syndrome based 
on whole transcriptome profiling by next-generation RNA sequencing of 
bladder mucosal biopsies. J Urol. 2019;202(2):290–300. https:// doi. org/ 10. 
1097/ ju. 00000 00000 000234.
 13. Sanchez Freire V, Burkhard FC, Kessler TM, Kuhn A, Draeger A, Monas-
tyrskaya K. MicroRNAs may mediate the down-regulation of neu-
rokinin-1 receptor in chronic bladder pain syndrome. Am J Pathol. 
2010;176(1):288–303. https:// doi. org/ 10. 2353/ ajpath. 2010. 090552.
 14. Gheinani AH, Kiss B, Moltzahn F, Keller I, Bruggmann R, Rehrauer H, et al. 
Characterization of miRNA-regulated networks, hubs of signaling, and 
biomarkers in obstruction-induced bladder dysfunction. JCI insight. 
2017;2(2):e89560. https:// doi. org/ 10. 1172/ jci. insig ht. 89560.
 15. Boyle EI, Weng S, Gollub J, Jin H, Botstein D, Cherry JM, et al. 
GO::TermFinder–open source software for accessing Gene Ontology 
information and finding significantly enriched Gene Ontology terms 
associated with a list of genes. Bioinformatics. 2004;20(18):3710–5. 
https:// doi. org/ 10. 1093/ bioin forma tics/ bth456.
 16. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for compar-
ing biological themes among gene clusters. OMICS. 2012;16(5):284–7. 
https:// doi. org/ 10. 1089/ omi. 2011. 0118.
 17. Gheinani AH, Vogeli M, Baumgartner U, Vassella E, Draeger A, Bur-
khard FC, et al. Improved isolation strategies to increase the yield and 
purity of human urinary exosomes for biomarker discovery. Sci Rep. 
2018;8(1):3945. https:// doi. org/ 10. 1038/ s41598- 018- 22142-x.
 18. Molania R, Gagnon-Bartsch JA, Dobrovic A, Speed TP. A new normaliza-
tion for Nanostring nCounter gene expression data. Nucleic Acids Res. 
2019;47(12):6073–83. https:// doi. org/ 10. 1093/ nar/ gkz433.
 19. Maeda D, Akiyama Y, Morikawa T, Kunita A, Ota Y, Katoh H, et al. Hunner-
type (classic) interstitial cystitis: a distinct inflammatory disorder char-
acterized by pancystitis, with frequent expansion of clonal B-cells and 
epithelial denudation. PLoS ONE. 2015;10(11):e0143316. https:// doi. org/ 
10. 1371/ journ al. pone. 01433 16.
 20. Homma Y, Akiyama Y, Tomoe H, Furuta A, Ueda T, Maeda D, et al. Clini-
cal guidelines for interstitial cystitis/bladder pain syndrome. Int J Urol. 
2020;27(7):578–89. https:// doi. org/ 10. 1111/ iju. 14234.
 21. Shrestha N, Bahnan W, Wiley DJ, Barber G, Fields KA, Schesser K. Eukary-
otic initiation factor 2 (eIF2) signaling regulates proinflammatory cytokine 
expression and bacterial invasion. J Biol Chem. 2012;287(34):28738–44. 
https:// doi. org/ 10. 1074/ jbc. M112. 375915.
 22. Noguchi K, Okubo M. Leukotrienes in nociceptive pathway and neuro-
pathic/inflammatory pain. Biol Pharm Bull. 2011;34(8):1163–9. https:// doi. 
org/ 10. 1248/ bpb. 34. 1163.
 23. Regauer S, Gamper M, Fehr MK, Viereck V. Sensory hyperinnervation 
distinguishes bladder pain syndrome/interstitial cystitis from overactive 
bladder syndrome. J Urol. 2017;197(1):159–66. https:// doi. org/ 10. 1016/j. 
juro. 2016. 06. 089.
 24. Honjoh K, Nakajima H, Hirai T, Watanabe S, Matsumine A. Relationship 
of inflammatory cytokines from M1-Type microglia/macrophages at 
the injured site and lumbar enlargement with neuropathic pain after 
spinal cord injury in the CCL21 knockout (plt) mouse. Front Cell Neurosci. 
2019;13:525. https:// doi. org/ 10. 3389/ fncel. 2019. 00525.
 25. Pickens SR, Chamberlain ND, Volin MV, Pope RM, Talarico NE, Mandelin 
AM 2nd, et al. Role of the CCL21 and CCR7 pathways in rheumatoid 
arthritis angiogenesis. Arthritis Rheum. 2012;64(8):2471–81. https:// doi. 
org/ 10. 1002/ art. 34452.
 26. Pierce EM, Carpenter K, Jakubzick C, Kunkel SL, Flaherty KR, Martinez FJ, 
et al. Therapeutic targeting of CC ligand 21 or CC chemokine receptor 
7 abrogates pulmonary fibrosis induced by the adoptive transfer of 
human pulmonary fibroblasts to immunodeficient mice. Am J Pathol. 
2007;170(4):1152–64. https:// doi. org/ 10. 2353/ ajpath. 2007. 060649.
 27. Hirshman NA, Hughes FM Jr, Jin H, Harrison WT, White SW, Doan I, et al. 
Cyclophosphamide-induced cystitis results in NLRP3-mediated inflam-
mation in the hippocampus and symptoms of depression in rats. Am J 
Physiol Renal Physiol. 2020;318(2):F354–62. https:// doi. org/ 10. 1152/ ajpre 
nal. 00408. 2019.
 28. Crawford A, Tripp DA, Nickel JC, Carr L, Moldwin R, Katz L et al. Depres-
sion and helplessness impact interstitial cystitis/bladder pain syndrome 
pain over time. Canadian Urological Association journal = Journal de 
l’Association des urologues du Canada. 2019;13(10):328–33. https:// doi. 
org/ 10. 5489/ cuaj. 5703.
 29. McKernan LC, Walsh CG, Reynolds WS, Crofford LJ, Dmochowski RR, 
Williams DA. Psychosocial co-morbidities in Interstitial Cystitis/Blad-
der Pain syndrome (IC/BPS): a systematic review. Neurourol Urodyn. 
2018;37(3):926–41. https:// doi. org/ 10. 1002/ nau. 23421.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
